A Phase I, Open-Label, Multi-Centre, Multiple Ascending Dose Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) in Patients With Acute Myeloid Leukaemia (AML).

Trial Profile

A Phase I, Open-Label, Multi-Centre, Multiple Ascending Dose Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) in Patients With Acute Myeloid Leukaemia (AML).

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jun 2011

At a glance

  • Drugs Barasertib (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 03 Mar 2011 Planned End Date changed from 1 Feb 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 09 Dec 2010 Planned End Date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 06 Oct 2010 New source identified and integrated (M.D. Anderson Cancer Center, 2009-0172).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top